Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.55 |
| ▸ | TEK | Q02763 | 4/20 | 0.55 |
| ▸ | RET | P07949 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | LYN | P07948 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | FES | P07332 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | FGR | P09769 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548658 | 0.86 | KDR (0.63) | KDRTEKRETLCKPDGFRB | |
| SCHEMBL4548657 | 0.86 | KDR (0.65) | KDRTEKRETLCKPDGFRB | |
| SCHEMBL2748320 | 0.83 | KDR (0.68) | KDRTEKLCKAURKAMET | |
| SCHEMBL4548734 | 0.82 | KDR (0.52) | KDRRETLCKPDGFRBAURKA | |
| SCHEMBL2747491 | 0.81 | KDR (0.78) | KDRTEKRETLCKPDGFRB | |
| SCHEMBL2437469 | 0.80 | KDR (0.71) | KDRRETLCKPDGFRBAURKA | |
| SCHEMBL4548733 | 0.79 | KDR (0.57) | KDRTEKRETLCKPDGFRB | |
| SCHEMBL4548735 | 0.78 | KDR (0.52) | KDRTEKRETLCKAURKA | |
| SCHEMBL2434005 | 0.78 | KDR (0.61) | KDRRETLCKPDGFRBAURKA | |
| SCHEMBL13603631 | 0.77 | DDR2 (0.63) | KDRTEKRETLCKPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885TEK 184/4885RET 138/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885TEK 184/4885RET 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.